Overview

Nirogacestat in Ovarian Granulosa Cell Tumors

Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.
Phase:
Phase 2
Details
Lead Sponsor:
SpringWorks Therapeutics, Inc.